Like sotorasib before it, adagrasib is a novel agent showing promising efficacy for the previously deemed “undruggable” KRAS-mutated non-small cell lung cancer.
Like sotorasib before it, adagrasib is a novel agent showing promising efficacy for the previously deemed “undruggable” KRAS-mutated non-small cell lung cancer.
